Overlapping but Distinct Role of p21WAF1/CDKN1 and Survivin in Hematopoietic Progenitor Cell Proliferation.

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 1334-1334
Author(s):  
Seiji Fukuda ◽  
Mariko Abe ◽  
Seiji Yamaguchi ◽  
Louis M. Pelus

Abstract Survivin is a member of the inhibitor of apoptosis protein family that has been implicated in cell cycle control, anti-apoptosis and cell division. Our previous studies and others have shown that Survivin and the cyclin dependent kinase inhibitor p21WAF1/CDKN1 (p21) are functionally associated and are involved in cell cycle, anti-apoptosis and cytokinesis in cancer cells and in normal hematopoietic progenitor cells (HPC). P21 is highly expressed in quiescent hematopoietic stem cells (HSC) in steady state, but the proportion of quiescent HSCs in G0 phase is reduced in p21−/− mice. In contrast, p21 has been shown as positive regulator on cell cycle of normal HPC since p21 deficiency results in fewer total CFU in mouse bone marrow (BM) cells with fewer CFU in S-phase and retrovirus transduction of p21 in p21 deficient bone marrow cells restores total and cycling CFU. We have previously reported that Survivin increases the proliferation of mouse primary HPC and that this enhancing effect is on HPC proliferation is absent when p21 is functionally deleted, suggesting that p21 is required for Survivin to enhance HPC proliferation. In addition, ITD-Flt3 mutations that are normally expressed in patients with acute myeloid leukemia and associate poor prognosis increase expression of both Survivin and p21, implicating their involvement in aberrant proliferation of HPC expressing ITD-Flt3. Herein we have characterized the functional association between p21 and Survivin in normal and transformed cell proliferation. Antagonizing wild-type Survivin in mouse BaF3 cells by retrovirus transduction of a T34A dominant negative mutant Survivin or anti-sense increased p21 expression, even though Survivin requires p21 to enhance HPC proliferation. Ectopic p21 in Survivin+/+ primary mouse bone marrow cells increased the number of immunophenotypically defined c-kit+, lin− (KL) cells, which is consistent with a positive role of p21 in HPC proliferation, however; ectopic expression of p21 failed to increase HPC proliferation in Survivin deficient primary bone marrow cells, suggesting that p21 alone is not sufficient to substitute for Survivin’s enhancing function on normal HPC proliferation. Over-expression of ITD-Flt3 enhanced growth factor independent proliferation of primary mouse marrow c-kit+, Sca-1+, lin− (KSL) cell number; however, co-expression of p21 with ITD-Flt3 dramatically decreased the number of growth factor independent KSL cells (80±6% reduction: P<0.01). Furthermore, the inhibitory effect of p21 on KLS proliferation was further enhanced by Survivin knockout bone marrow cells (64±5% reduction compared with presence of Survivin: P<0.05). These findings indicate that Survivin and p21 have a overlapping but distinct roles in regulating normal HPC proliferation and that manipulating p21 and Survivin may represent a potential therapeutic target for acute leukemia cells expressing ITD-Flt3.

2017 ◽  
Vol 37 (suppl_1) ◽  
Author(s):  
Sara McCurdy ◽  
William A Boisvert

Macrophage accumulation is a key process affecting all stages of atherosclerosis. Whether these cells accumulate in plaque solely by recruitment of monocytes from circulation or by proliferation within the plaque is an important question that has garnered much interest in recent years. Originally identified as a lymphocyte activation marker, CD98hc (SLC3A2) is a transmembrane protein involved in cell proliferation and survival via integrin signaling and MAP kinase activation. We hypothesized that CD98hc deficiency in myeloid cells would have a protective effect on atherosclerosis development and plaque composition by limiting macrophage proliferation. For the studies described, we utilized mice with myeloid-specific deletion of the CD98hc ( CD98hc fl/fl LysMCre + ) to determine the effects of CD98hc deficiency on macrophage function in the context of atherosclerosis . We performed in vitro assays to investigate the role of CD98hc in the proliferation and survival of primary mouse bone marrow derived macrophages. Although we found no differences in the number of bone marrow cells isolated from control or CD98hc -/- animals, after differentiation with MCS-F for 7 days, the number of macrophages obtained from CD98hc -/- mice was approximately 80% lower (7.2 ± 2.2 x 10 6 vs. 42.4 ± 4.6 x 10 6 per mouse) compared to control mice. Proliferation assays in vitro using EdU revealed approximately 50% (15.4 ± 2.5% vs. 7.5±1.8%) reduced cell proliferation in CD98hc -/- macrophages compared to control cells that could not be rescued with the addition M-CSF. In a 6-week atherosclerosis study using Ldlr -/- CD98hc fl/fl LysMCre + mice, Oil-Red O staining of whole aortae as well as aortic sinus sections showed that atherosclerotic plaque development was reduced compared to Ldlr -/- CD98hc fl/fl LysMCre - control mice. Additionally, immunohistochemical staining of atherosclerotic tissues revealed a reduction in macrophage abundance and proliferation within the plaque of Ldlr -/- CD98hc fl/fl LysMCre + mice compared to control mice. These findings support an important role of CD98hc in macrophage proliferation within the plaque environment, and provide a novel target for reducing atherosclerosis.


2011 ◽  
Vol 106 (08) ◽  
pp. 337-343 ◽  
Author(s):  
Jianhui Wang ◽  
Zanhua Yi ◽  
Shiyang Wang ◽  
Zongdong Li

SummaryThrombocytopenia is a common feature of myelodysplastic syndromes (MDS). 5-aza-2’-deoxycytidine (decitabine) has been used to treat MDS with an approximately 20% response rate in thrombocytopenia. However, the mechanism of how decitabine increases platelet count is not clear. In this study, we investigated the effect of decitabine on megakaryocyte maturation and platelet release in the mouse. The effect of decitabine on megakaryocyte maturation was studied in an in vitro megakaryocyte differentiation model utilising mouse bone marrow cells and mouse megakaryoblastic cell line L8057. Decitabine (2.5 μM) is able to induce L8057 cells to differentiate into a megakaryocyte-like polyploidy cells with positive markers of acetylcholinesterase and αIIb integrin (CD41). Higher expression of αIIb integrin was also found in primary mouse bone marrow cells and human cord blood CD34+ cells cultured with both thrombopoietin and decitabine as compared to thrombopoietin alone. In addition, we noted a 30% platelet count increase in Balb/c mice 12 hours after the injection of decitabine at a clinically relevant dose (15 mg/m2), suggesting a rapid platelet release from the spleen or bone marrow. Our data suggest that decitabine increases platelet counts by enhancing platelet release and megakaryocyte maturation.


Blood ◽  
2000 ◽  
Vol 95 (9) ◽  
pp. 2913-2921 ◽  
Author(s):  
Robert C. Quackenbush ◽  
Gary W. Reuther ◽  
Juli P. Miller ◽  
Kevin D. Courtney ◽  
Warren S. Pear ◽  
...  

The reciprocal translocation between chromosomes 9 and 22 that fuses coding sequences of the Bcr and Abl genes is responsible for a remarkably diverse group of hematologic malignancies. A newly described 230-kd form of Bcr-Abl has been associated with an indolent myeloproliferative syndrome referred to as chronic neutrophilic leukemia. We have cloned the corresponding gene and examined the biologic and biochemical properties of p230 Bcr-Abl after retroviral-mediated gene transfer into hematopoietic cell lines and primary bone marrow cells. p230 Bcr-Abl–expressing 32D myeloid cells were fully growth factor-independent and activated similar signal transduction pathways as the well-characterized p210 and p185 forms of Bcr-Abl. In contrast, primary mouse bone marrow cells expressing p230 required exogenous hematopoietic growth factors for optimal growth, whereas p185- and p210-expressing cells were independent of growth factors. The 3 Bcr-Abl proteins exerted different effects on differentiation of bone marrow cells. p185 induced outgrowth of lymphoid precursors capable of tumor formation in immunodeficient mice. In contrast, p210- and p230-expressing bone marrow cells caused limited outgrowth of lymphoid precursors that failed to form tumors in immunodeficient mice. Removal of cytokines and autologous stroma from Bcr-Abl–expressing bone marrow cultures produced the expansion of distinct lineages by the various Bcr-Abl proteins. p185 drove expansion of cytokine-independent lymphoid progenitors, while p210 and p230 generated cytokine-independent monocyte/myeloid cells. These findings suggest that the different Bcr-Abl fusion proteins drive the expansion of different hematopoietic populations, which may explain the association of the various Bcr-Abl oncoproteins with different spectra of human leukemias.


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 4175-4175
Author(s):  
Mariko Abe ◽  
Louis M. Pelus ◽  
Pratibha Singh ◽  
Seiji Yamaguchi ◽  
Takeshi Taketani ◽  
...  

Abstract Abstract 4175 Internal Tandem Duplication mutations in the Flt3 tyrosine kinase gene (ITD-Flt3) induce constitutive activation of Flt3 signaling and are frequently found in acute myeloid leukemia patients with poor prognosis. We have previously reported that Survivin enhances proliferation of mouse primary hematopoietic progenitor cells (HPC) and that this enhancing effect on HPC proliferation is absent when p21WAF1/CDK1 (p21) is deleted, suggesting that p21 is required for Survivin to enhance normal HPC proliferation by hematopoietic growth factors (Fukuda et al. Blood 2004). Our subsequent studies showed that several ITD-Flt3 mutations increase expression of both Survivin and p21 and enhance growth factor independent HPC proliferation through up regulation of Survivin (Fukuda et al. Blood 2009). These findings suggest that p21 may also regulate growth factor independent HPC proliferation mediated by ITD-Flt3. However, our previous studies and those of others suggest that p21 function can vary and affect cell proliferation in diverse ways depending on cell type, and that intracellular signals generated by the wild-type Flt3 and ITD-Flt3 receptors can be qualitatively different. In the present study, we evaluated functional differences in the Survivin/p21 axis between wild-type Flt3 versus ITD-Flt3 signaling on HPC proliferation using p21-/- mouse bone marrow cells. P21 gene deletion significantly enhances growth factor independent proliferation of ITD-Flt3 transduced CFU-GM in vitro compared to p21+/+ mice (221±5% increase: P<0.02), suggesting that p21 inhibits growth factor independent proliferation of HPC by ITD-Flt3. This is in contrast to Survivin deletion, which significantly reduced growth factor-independent CFU-GM proliferation (74% reduction, P<0.05). Similar to ITD-Flt3, Flt3 ligand (FL) induced marginal expression of p21 in Ba/F3 cells expressing wild-type Flt3 and stimulated proliferation of p21+/+ CFU-GM transduced with wild-type Flt3. In contrast to the negative role of p21 in ITD-Flt3 mediated growth factor independent HPC proliferation, p21 deletion significantly reduced proliferation of CFU-GM over-expressing wild-type Flt3 and incubated with FL compared to p21+/+ CFU-GM (59±6% reduction: P<0.01), indicating that p21 positively regulates proliferation of HPC stimulated by wild-type Flt3 signaling, which is consistent with our report and others where p21-/- CFU-GM incubated with GM-CSF and/or SCF were significantly decreased compared to p21+/+ cells (Mantel et al. Blood 1996, Fukuda et al. Blood 2004). Our data indicates that while both wild-type Flt3 and ITD-Flt3 signaling up-regulate p21, wild-type Flt3 and ITD-Flt3 differentially modify p21 function that inversely regulates proliferation of HPC. The positive regulatory role of p21 in HPC proliferation by wild-type Flt3 signaling is in good agreement with our study that the Survivin/p21 axis positively regulates growth factor dependent HPC proliferation. This suggests that the Survivin/p21 axis may enhance HPC proliferation in the presence of wild-type Flt3 signaling. In contrast, p21 negatively regulates aberrant growth factor independent proliferation in primary HPC transformed by ITD-Flt3, whereas Survivin positively regulates ITD-Flt3 signaling, suggesting that the Survivin/p21 functional axis does not exist or play a role in aberrant growth factor independent proliferation by ITD-Flt3 signaling as opposed to normal HPC proliferation. Our study uncovers one functional difference between wild-type Flt3 and ITD-Flt3 signaling that may aid in developing specific therapeutic molecules for ITD-Flt3+ hematological malignancies that target ITD-Flt3+ transformed cells without affecting normal hematopoiesis. Disclosures: No relevant conflicts of interest to declare.


2008 ◽  
Vol 49 (4) ◽  
pp. 437-443 ◽  
Author(s):  
Kanokporn Noy RITHIDECH ◽  
Marc GOLIGHTLY ◽  
Elbert WHORTON

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 482-482
Author(s):  
Matthew D. Cheney ◽  
Yizhou Liu ◽  
Yunpeng Zhou ◽  
Maksymilian Chruszcz ◽  
Thomas M. Laue ◽  
...  

Abstract AML1/ETO is the chimeric fusion protein resulting from the t(8;21) found in AML of the M2 subtype. It contains the N-terminal 177 amino acids of RUNX1 and virtually all (575aa) of ETO. The RUNX1 component includes the Runt domain, which mediates both DNA binding and heterodimerization with CBFβ, but lacks the more C-terminal sequences required for transactivation. AML1/ETO occupies RUNX target genes in vivo and is associated with a repressive chromatin structure characterized by reduced levels of acetylated histone H3. AML1/ETO is thought to repress transcription by recruiting a SMRT (N-CoR)/Sin3A/HDAC complex to chromatin via sequences in ETO. ETO is the human homologue of the Drosophila Nervy protein and shares 4 regions of homology with Nervy called Nervy Homology Regions (NHR) 1–4. Deletion studies have shown that three of the AML1/ETO domains essential for its repressive function are the Runt domain, NHR2, and NHR4. The NHR2 domain is a hydrophobic heptad repeat that mediates oligomerization of AML1/ETO, interaction with ETO family members, and also with mSin3A and HDACs. We recently solved an x-ray structure of the NHR2 domain and found it to be an alpha-helical tetramer. Based on this structure we have introduced amino acid substitutions into the NHR2 domain that disrupt tetramer formation but not AML1/ETO stability. These mutations impair the ability of AML1/ETO to inhibit the differentiation of GR-1+/Mac-1+ cells following retroviral transduction into primary mouse bone marrow cells, and also inhibit the serial replating ability of AML1/ETO expressing bone marrow cells in vitro. We additionally show that mutations reported by Amann et al. (Mol Cell Biol. 21, 6470, 2001) to disrupt mSin3A binding to NHR2 do not affect the biological activity of AML1/ETO in vitro. We also introduced mutations in the Runt domain of AML1/ETO that disrupt CBFβ binding by defined amounts (40-fold, 200-fold, 500-fold), and demonstrated that CBFβ binding by AML1/ETO is essential for its dominant negative activity. The latter results suggest that small molecules designed to selectively impair heterodimerization of AML1/ETO with CBFβ could potentially block AML1/ETO’s dominant negative activity.


Sign in / Sign up

Export Citation Format

Share Document